Company news

Ocugen, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ocugen to Host Conference Call on Friday, August 1 at 8: 30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

July 16, 2025

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

June 22, 2025

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

June 15, 2025

Ocugen To Present at BIO International Convention 2025

June 10, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

June 4, 2025

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 26, 2025

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 8, 2025

Ocugen to Host Conference Call on Friday, May 9 at 8: 30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 1, 2025

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

April 28, 2025

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

April 7, 2025

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

March 17, 2025

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

March 4, 2025

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

March 2, 2025

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

February 26, 2025

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8: 30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

February 20, 2025

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

February 11, 2025

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

February 2, 2025

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

January 26, 2025

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

January 15, 2025

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

January 12, 2025

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

December 18, 2024

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

November 26, 2024

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

November 19, 2024

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

November 18, 2024

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

November 7, 2024

Ocugen Secures $30 Million in Debt Funding

November 6, 2024

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

October 27, 2024

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

October 21, 2024

Ocugen to Host Conference Call on Friday, November 8 at 8: 30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

October 16, 2024

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

October 9, 2024

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

October 8, 2024

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

October 1, 2024

Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference

September 23, 2024

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

September 8, 2024

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

September 4, 2024

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

August 27, 2024

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

August 25, 2024

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

August 7, 2024

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

August 4, 2024

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

August 1, 2024

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

July 30, 2024

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

July 30, 2024

Ocugen to Host Conference Call on Thursday, August 8 at 8: 30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

July 28, 2024

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

July 24, 2024

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

June 20, 2024

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

June 19, 2024

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

May 30, 2024

Ocugen to Present at BIO International Convention 2024

May 28, 2024

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

May 27, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 75 decks. Every deck is listed under its year.